期刊文献+

Exendin-4对游离脂肪酸诱导肝细胞sirt6表达及其对糖异生作用的影响 被引量:3

Effect of Exendin- 4 on the Expression of Sirt6 and Hepatic Gluconeogenesis in the Free Fatty Acid- induced Hep G2 Cell
下载PDF
导出
摘要 目的观察Exendin-4对游离脂肪酸诱导的肝细胞sirt6表达的影响及其在肝脏糖异生过程中的调控作用。方法体外培养人肝癌细胞株Hep G2细胞,根据干预措施分为正常对照组、Exendin-4(100nmol/L)处理组、游离脂肪酸对待组、游离脂肪酸+Exendin-4处理组。Western blot法检测各组细胞中sirt6表达的变化。以stealth siRNA干扰Hep G2细胞中sirt6的表达后给予相同处理,Western blot法检测sirt6表达蛋白水平的变化,RT-PCR检测sirt6及糖异生相关基因G6Pase和PEPCK mRNA水平的变化。结果与正常对照组相比游离脂肪酸可显著降低肝细胞内sirt6蛋白的表达,而经Exendin-4处理后,sirt6表达显著升高。与正常对照组相比,游离脂肪酸可诱导肝细胞糖异生相关基因表达的升高,经过Exendin-4处理后,可相应降低上述基因的表达。当下调sirt6表达后,则抑制了由Exendin-4对改善游离脂肪酸诱导肝细胞糖异生相关基因的调节作用。结论游离脂肪酸可降低肝细胞sirt6的表达,Exendin-4可改善由游离脂肪酸诱导的肝细胞sirt6表达的下降及糖异生相关基因表达的升高;Exendin-4可能是通过对sirt6的调节从而在肝脏糖异生过程中发挥重要作用的。 Objective To examine the influence of Exendin -4 on the experssion of sift6 and other related gluconeogenesis genes in fatty liver cell culture model. Methods HepG2 ceils were randomly divided into 4 groups : normal control group, Exendin - 4 ( lOOnmol/ L) treated group, FFA treated group, FFA ± Exendin -4 (lOOnmol/L) treated group. Western blot was used to detect the expression of sift6. Stealth siRNA was used to inhibit the expression of sirt6. After the treatment,the mRNA of Sirt6 and hepatic gluconeogenesis gene G6Pase,PEPCK were detected by RT - PCR. Results Compared with the control group,the sirt6 protein expression level was decreased in FFA - stimulated HepG2 cells. However, 100nmol/L Exendin - 4 treatment could improve the FFA - decreased the expression of sirt6. Exendin -4 treatment significantly reduced the mRNA level of G6Pase and PEPCK induced by the FFAs. However, when down -regula- ted the expression of sirt6 by siRNA, the effects of Exendin - 4 on the hepatic gluconeogenic improvement had been diminished. Conclu- sion FFAs could decrease the expression of sirt6 in HepG2 ceils. Exendin - 4 reverse the down - regulation of sirt6 induced by the FFAs. Exendin -4 treatment may attenuate and improve hepatic gluconeogenesis in liver tissues through the activation of sirt6 signaling cascade.
出处 《医学研究杂志》 2015年第1期39-43,共5页 Journal of Medical Research
基金 国家自然科学基金资助项目(81370956) 上海交通大学专项基金资助项目(2011JDZX021)
关键词 胰高血糖素样肽-1 糖异生 脂肪肝 Glucagon - like peptide - 1 Gluconeogenesis NAFLD
  • 相关文献

参考文献16

  • 1Loria P, Lonardo A, Bellentani S, et al. Non - alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question[ J]. Nutr Metab Cardiovasc Dis ,2007,17 ( 9 ) :684 - 698.
  • 2Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxieity in nonalcoholic fat- ty liver disease: not all lipids are created equal[ J]. Expert Rev Gas- troenterol Hepatol, 2009,3 ( 4 ) :445 - 451.
  • 3Montanya E. A comparison of currently available GLP - 1 receptor ag- onists for the treatment of type 2 diabetes[ J]. Expert Opin Pharmaco- ther,2012,13(10) :1451 - 1467.
  • 4Zhong L, Mostoslavsky R. SIRT6: a master epigenetic gatekeeper of glucose metabolism[ J]. Transcription ,2010,1 ( 1 ) : 17 - 21.
  • 5Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non- alcoholic fatty liver disease [ J ]. J Clin Invest, 2005,115 ( 5 ) : 1343 - 1351.
  • 6Gomez - Leehon M J, Donato MT, Martinez - Romero A, et al. A hu- man hepatocellular in vitro model to investigate steatosis [ J]. Chem Biol Interact,2007,165 ( 2 ) : 106 - 116.
  • 7Drucker D J, Nauck MA. The incretin system: glucagon - llke peptide - 1 receptor agonists and dipeptidyl peptidase -4 inhibitors in type 2 diabetes [ J ]. Lancet,2006,368 ( 9548 ) : 1696 - 1705.
  • 8Gupta NA, Mells J, Dunham RM, et al. Glucagon - like peptide - 1 receptor is present on human hepatocytes and has a direct role in de- creasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[ J]. Hepatology,2010,51 (5) : 1584 - 1592.
  • 9Cuthbertson JD, Taylor RJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon - like peptide-1(GLP- 1) receptor agonists[J]. Angew Chem Int Ed Engl, 2013,52(5) :1490 - 1493.
  • 10Gupta NA, Kolachala VL, Jiang R,et al. The glucagon -like peptide - 1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipot- ysis[ J]. Am J Pathol,2012,181 (5) : 1693 - 1701.

同被引文献27

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部